Selective Functionalization of Silyl-N-Cbz-1,3-Thiazolidines with Aldehydes to Homologated α-Hydroxy Thiazolidines and Fused Oxazolidinones

Alessandro Degl’Innocenti; Antonella Capperucci; Irene Malesci; Giulio Castagnoli; Miriam Acciai; Tiziano Nocentini; Salvatore Pollicino

doi:10.1055/s-2006-949633

LETTER

Selective Functionalization of Silyl-N-Cbz-1,3-Thiazolidines with Aldehydes to Homologated α-Hydroxy Thiazolidines and Fused Oxazolidinones

Alessandro Degl’Innocenti*^a, Antonella Capperucci*^a, Irene Malesci^a, Giulio Castagnoli^a, Miriam Acciai^a, Tiziano Nocentini^a, Salvatore Pollicino^b
^a Department of Organic Chemistry, Laboratory of Design, Synthesis and Study of Biologically Active Heterocycles (HeteroBioLab), via della Lastruccia 13, 50019 Sesto Fiorentino (Firenze), Italy
^b Department of Organic Chemistry, ‘A. Mangini’, viale Risorgimento 4, 40136 Bologna, Italy
Fax: +39(055)4573585; e-Mail: alessandro.deglinnocenti@unifi.it;

Abstract

Alle Artikel dieser Rubrik

Abstract

N-Cbz-2-trimethylsilyl-1,3-thiazolidine can be easily functionalized under fluoride ion conditions with aldehydes as electrophiles. The reaction selectively affords new cyclo-fused oxazolidinones or homologated α-hydroxy thiazolidines depending on the temperature of the reaction and the nature of the aldehyde.

Key words

silyl thiazolidines - fluoride-ion catalysis - cyclization - bicyclic compounds - fused oxazolidinones

Volltext

Referenzen

References and Notes

1a Nakasawa HT. Goon DJW. Muldoon WP. Zera RT. J. Med. Chem. 1984, 27: 591

1b Samanen J. Cash T. Narindray D. Brandeis E. Adams W. Weidemann H. Yellin T. J. Med. Chem. 1991, 34: 3036

1c Wonacott A. Cooke R. Hayes FR. Hann MM. Jhoti H. McMeekin P. Mistry A. Murray-Rust P. Singh OMP. J. Med. Chem. 1993, 36: 3113

See, for example:

2a Chemistry and Biology of β-lactam Antibiotics Vol. 1-3: Morrin RB. Gorman M. Academic Press; New York: 1982.

2b The Organic Chemistry of β-Lactams George GI. VCH; New York: 1993.

2c The Chemistry of β-Lactams Page MI. Blackie Academic and Professional; New York: 1996.

3a Walsh CT. Science 2004, 303: 1805

3b Wöhr T. Nahl F. Nefzi A. Rohwedder B. Sato T. Sun X. Mutter M. J. Am. Chem. Soc. 1996, 118: 9218

3c Botti P. Pallin DT. Tam JP. J. Am. Chem. Soc. 1996, 118: 10018

4 Gandolfi CA. Di Domenico R. Spinelli S. Gallico L. Fiocchi L. Lotto A. Menta E. Borghi A. Dalla Rosa C. Tognella S. J. Med. Chem. 1995, 38: 508

5a Westland RD. Lin MH. Cooley RA. Zwiesler ML. Grenan MM. J. Med. Chem. 1973, 16: 328

5b Farmer PS. Leung C.-C. Lui EMK. J. Med. Chem. 1973, 16: 411

5c Wilmore BH. Cassidy PB. Warters RL. Roberts JC. J. Med. Chem. 2001, 44: 2661

6 Faury P. Camplo M. Charvet A.-S. Mourier N. Barthelemy P. Graciet J.-C. Kraus J.-L. J. Heterocycl. Chem. 1994, 31: 1465

7a Engel W, Schieberle P, Guntert M, and Lambrecht S. inventors; Eur. Patent 1069116. ; Chem. Abstr. 2001, 134, 85321

7b Schmidt CO. Krammer GE. Weber B. Stoeckigt D. Herbrand K. Ott F. Kindel G. Brennecke S. Gatfield IL. Bertram H.-J. Perfum. Flavor. 2005, 30: 28

8 Dubs O, Kuentzel H, Pesaro M, and Schmidt H. inventors; Patentschrift (Switz.). ; Chem. Abstr. 1977, 87, 201514

9a Schneider PH. Schrekker HS. Silveira CC. Wessjohann LA. Braga AL. Eur. J. Org. Chem. 2004, 2715

9b Cremonesi G. Dalla Croce P. Fontana F. Forni A. La Rosa C. Tetrahedron: Asymmetry 2005, 16: 3371

10a Wang L. Nakamura S. Ito Y. Toru T. Tetrahedron: Asymmetry 2004, 15: 3059

10b Wang L. Nakamura S. Toru T. Org. Biomol. Chem. 2004, 2: 2169

11 Gawley RE. Zhang Q. McPhail AT. Tetrahedron: Asymmetry 2000, 11: 2093

12 Meyers A. I., Edwards P. D., Rieker W. F., Bailey T. R.; J. Am. Chem. Soc.; 1984, 106: 3270

13a Degl’Innocenti A. Capperucci A. Nocentini T. Tetrahedron Lett. 2001, 42: 4557

13b Capperucci A. Ceré V. Degl’Innocenti A. Nocentini T. Pollicino S. Synlett 2002, 1447

14 Capperucci A. Degl’Innocenti A. Nocentini T. Mordini A. Biondi S. Dini F. Lett. Org. Chem. 2004, 1: 55

15

Typical Procedure: A solution of thiazolidine (1, 50 mg, 0.17 mmol), benzaldehyde (2a, 36 mg, 0.34 mmol) and activated MS (4 Å, 300 mg) was stirred at r.t. in freshly distilled THF (3 mL) under an inert atmosphere. TBAF (68 mL of a 1 M THF solution, 0.07 mmol) was added dropwise (0.2 equiv every hour). The mixture was stirred at r.t. and progression of the reaction was monitored by TLC. The reaction was quenched with H₂O and the product was extracted into Et₂O (2 mL). The resulting organic layer was washed with brine, dried over Na₂SO₄ and the solvent evaporated under vacuum. Purification using column chromatography (hexane-EtOAc, 4:1) afforded 13 mg (34%) of anti-3a and 13 mg (34%) of syn-3a. anti-3a: ¹H NMR (200 MHz, CDCl₃): δ = 3.04-3.15 (m, 2 H), 4.42-4.53 (m, 2 H), 4.99 (d, J = 1.8 Hz, 1 H), 5.52 (d, J = 1.8 Hz, 1 H), 7.36-7.42 (m, 5 H); ¹³C NMR (50 MHz, CDCl₃): δ = 30.5, 40.5, 72.0, 79.9, 127.2, 127.4, 128.1, 138.3, 157.4; MS: m/z (%) = 221 (49) [M⁺], 130 (32), 115 (55), 91 (100), 87 (90), 77 (34). syn-3a: ¹H NMR (200 MHz, CDCl₃): δ = 2.90-3.01 (m, 2 H), 3.10-3.25 (m, 1 H), 4.36-4.44 (m, 1 H), 5.41 (d, J = 5.8 Hz, 1 H), 5.92 (d, J = 5.8 Hz, 1 H), 7.20-7.45 (m, 5 H). ¹³C NMR (50 MHz, CDCl₃): δ = 30.3, 41.5, 69.9, 81.2, 127.2, 127.6, 128.3, 138.6, 157.4. MS: m/z (%) = 221 (31) [M⁺], 130 (36), 115 (39), 91 (100), 87 (78), 77 (38).

16

Variable amounts of benzyloxytrimethylsilane were detected in the reactions affording cyclic compounds 3. However, we were unable to detect silylated derivatives of 5 even before work-up, either under TLC or GC/MS conditions.

17

Characterization of Compounds 3g and 5g: diastereomers were separated by preparative TLC (silica gel, hexane-EtOAc, 4:1). 7-(Thiophen-2-yl)tetrahydroxooxazolo[4,3- b ]thiazol-5-one ( 3g): (anti-3g): ¹H NMR (200 MHz, CDCl₃): δ = 2.95-3.10 (m, 2 H), 4.40-4.50 (m, 2 H), 5.14 (d, J = 1.6 Hz,1 H), 5.74 (d, J = 1.6 Hz, 1 H), 7.00-7.10 (m, 1 H), 7.14-7.20 (m, 1 H), 7.28-7.40 (m, 1 H); ¹³C NMR (50 MHz, CDCl₃): δ = 31.8, 49.4, 71.3, 78.1, 126.8, 127.0, 127.1, 146.1, 157.6; MS: m/z (%) = 227 (74) [M⁺], 183 (19), 136 (33), 128 (29), 127 (47) 115 (50), 97 (26), 91 (40), 87 (100), 60 (59). (syn-3g): ¹H NMR (200 MHz, CDCl₃): δ = 2.95-3.10 (m, 2 H), 4.40-4.50 (m, 2 H), 5.36 (d, J = 5.6 Hz, 1 H), 6.10 (d, J = 5.6 Hz, 1 H), 7.00-7.10 (m, 1 H), 7.14-7.20 (m, 1 H), 7.28-7.40 (m, 1 H); ¹³C NMR (50 MHz, CDCl₃): δ = 31.3, 49.7, 71.5, 77.8, 126.6, 126.8, 127.0, 145.6, 157.6; MS: m/z (%) = 227 (8) [M⁺], 149 (26), 111 (54), 97 (38), 91 (100), 71 (55). 1-[2-(Hydroxy(thiophen-2-yl)methyl]thiazolidin-3-yl)-2-phenylethanone ( 5g): (anti-5g): ¹H NMR (200 MHz, CDCl₃): δ = 2.50-2.70 (m, 1 H), 2.70-2.90 (m, 1 H), 3.20-3.50 (m, 1 H), 3.95-4.20 (m, 1 H), 5.15 (d, J = 6.6 Hz, 1 H), 5.19 (m, 2 H), 5.44 (d, J = 6.6 Hz, 1 H), 7.00-7.10 (m, 1 H), 7.14-7.30 (m, 2 H), 7.32-7.45 (m, 5 H); ¹³C NMR (50 MHz, CDCl₃): δ = 31.3, 49.4, 68.0, 71.5, 74.5, 125.7, 126.6, 127.0, 128.1, 128.3, 128.6, 135.0, 151.1. (syn-5g): ¹H NMR (200 MHz, CDCl₃): δ = 2.50-2.70 (m, 1 H), 2.70-2.90 (m, 1 H), 3.79-3.91 (m, 1 H), 4.20-4.35 (m, 1 H), 5.19 (m, 2 H), 5.29 (br s, 1 H), 5.52 (br s, 1 H), 7.00-7.10 (m, 1 H), 7.14-7.32 (m, 2 H), 7.33-7.46 (m, 5 H).

18

anti -Benzyl 2-[hydroxy(phenyl)methyl]thiazolidine-3-carboxylate (anti-5a): ¹H NMR (200 MHz,CDCl₃): δ = 2.38-2.60 (m, 1 H), 2.61-2.80 (m, 1 H), 3.10-3.40 (m, 1 H), 3.92-4.19 (m, 1 H), 4.87 (d, J = 6.6 Hz, 1 H), 5.16 (m, 2 H), 5.45 (d, J = 6.6 Hz, 1 H), 7.18-7.45 (m, 10 H); ¹³C NMR (50 MHz, CDCl₃): δ = 30. 5, 49.4, 68.0, 71.6, 79.0, 125.5, 127.3, 128.2, 128.4, 134.9, 136.0, 150.9.

19

A referee suggested that one equivalent of fluoride is necessary for total reaction with benzaldehydes substituted with an electron-withdrawing group because there may be an ineffective TMS transfer in these cases. In this event a classical nucleophilic reaction involving the complete desilylation by fluoride would operate.